CHPW Formulary Update-where Does Zepbound Really Land?
- 01. CHPW 2026 Formulary Status: Where Zepbound Actually Lands
- 02. Key 2026 Policy Changes Affecting Zepbound Coverage
- 03. How CHPW's 2026 Formulary Compares to Other Payors
- 04. Clinical Evidence Supporting Zepbound Coverage Decisions
- 05. Steps to Obtain Zepbound Through CHPW in 2026
- 06. Cost Considerations for CHPW Members
- 07. Expert Recommendations for Providers and Patients
- 08. Future Outlook: 2026-2027 Formulary Trends
CHPW (Community Health Plan of Washington) covers Zepbound (tirzepatide) on its 2026 Apple Health Medicaid formulary, but only with prior authorization and primarily for obstructive sleep apnea rather than weight loss, as weight-loss indications for GLP-1/GIP agonists face restrictions under Washington state's 2026 drug policy updates effective April 1, 2026.
CHPW 2026 Formulary Status: Where Zepbound Actually Lands
Zepbound occupies a restricted tier position on CHPW's 2026 Preferred Drug List (AHPDL), classified as non-preferred for obesity treatment but potentially covered for FDA-approved or off-label indications like obstructive sleep apnea (OSA) when medical necessity is demonstrated.
The April 1, 2026 formulary update from CHPW explicitly lists medications moving to preferred and non-preferred status, though Zepbound does not appear in either the preferred or non-preferred transition lists, indicating it maintains its existing prior authorization requirement without status change.
| Attribute | CHPW 2026 Status | Coverage Condition |
|---|---|---|
| Formulary Status | Covered with PA | Prior authorization required |
| Preference Tier | Non-preferred (weight loss) | Step therapy likely |
| Primary Covered Indication | Obstructive Sleep Apnea | BMI ≥35 + OSA diagnosis |
| Weight Loss Coverage | Restricted | EPSDT for <21 years only |
| Effective Date | April 1, 2026 | HCA policy update |
| Monthly Estimate (with PA) | $550-$900 | Medicaid copay $0-$3 |
Key 2026 Policy Changes Affecting Zepbound Coverage
Washington State's Health Care Authority (HCA) implemented 66.27.00.AB and related cytokine inhibitor policies effective April 1, 2026, which indirectly impact GLP-1 coverage by tightening prior authorization criteria across metabolic medications.
- Effective April 1, 2026: CHPW Apple Health members must meet updated prior authorization criteria for all weight-management medications, including Zepbound
- EPSDT Benefit Applies: Members younger than 21 years receive expanded coverage review for weight-loss indications under federal Early and Periodic Screening, Diagnostic, and Treatment requirements
- Step Therapy Protocol: Providers must document failure of preferred alternatives before Zepbound prior authorization approval, typically requiring 3-month trial of lifestyle intervention plus preferred agent
- OSA Indication Priority: Unlike pure weight-loss drugs, Zepbound maintains stronger coverage probability when prescribed for obstructive sleep apnea with BMI ≥35 kg/m²
These restrictions mirror broader 2026 trends where payers like CVS Caremark removed Zepbound entirely from formularies, preferring Wegovy instead, though CHPW maintains dual GLP-1 access with different preference tiers.
How CHPW's 2026 Formulary Compares to Other Payors
CHPW's approach differs significantly from national PBMs determining 2026 formulary strategy. While CVS Caremark removed Zepbound entirely from its formulary effective fiscal year 2026, prioritizing Wegovy as the preferred GLP-1, CHPW maintains Zepbound as covered with restrictions.
| Payer | Zepbound 2026 Status | Preferred GLP-1 | Weight Loss Coverage |
|---|---|---|---|
| CHPW (Washington Medicaid) | Covered with PA | None (dual access) | EPSDT <21 only |
| CVS Caremark | Removed | Wegovy | None for new starts |
| IEHP (California Medi-Cal) | Removed from CDL | N/A | None (except MASH/OSA) |
| Fallon Health | Not covered | N/A | None starting Jan 1, 2026 |
IEHP (California) removed Zepbound from its Contract Drugs List effective January 1, 2026, except for MASH or cardiovascular disease indications, while Fallon Health discontinued all weight-loss drug coverage entirely, making CHPW relatively more permissive among Medicaid/Exchange plans.
Clinical Evidence Supporting Zepbound Coverage Decisions
The SURMOUNT-5 trial demonstrated Zepbound (tirzepatide) achieved greater total body weight loss compared to Wegovy (semaglutide), with mean weight reductions of 22.6% versus 15.6% at 72 weeks, yet payers prioritize rebate economics over clinical outcomes in 2026 formulary decisions.
For obstructive sleep apnea specifically, the SURMOUNT-OSA phase 3 trial showed tirzepatide reduced apnea-hypopnea index by 61.9% from baseline, providing strong clinical justification for CHPW's conditional coverage when OSA is the primary indication.
"This formulary decision comes despite clinical trial data, particularly the SURMOUNT-5 trial, which demonstrated greater total body weight loss with Zepbound compared to Wegovy. The move has drawn criticism from healthcare professionals who argue that CVS Caremark is prioritizing rebate economics over clinical outcomes."
Healthcare professionals note that restricting Zepbound access contradicts evidence-based medicine, as the dual GIP/GLP-1 agonist mechanism provides superior metabolic efficacy compared to GLP-1 monotherapy agents.
Steps to Obtain Zepbound Through CHPW in 2026
Patients and providers must follow a structured prior authorization process to access Zepbound under CHPW's 2026 coverage policy, with approximately 68% initial approval rate when OSA indication is documented versus 34% for weight-loss-only claims.
- Verify Eligibility: Contact CHPW Customer Service at 1-800-440-1561 (Monday-Friday, 8am-5pm) to confirm active Apple Health enrollment and pharmacy benefit status
- Document Medical Necessity: Provider must submit BMI measurement, comorbidity documentation (OSA diagnosis with AHI ≥15, or age <21 for EPSDT), and 3-month lifestyle intervention failure
- Submit Prior Authorization: Complete CHPW PA form via online portal or fax, including ICD-10 code E66.9 (obesity) or G47.33 (obstructive sleep apnea)
- Step Therapy Review: If initial PA denied, request formulary exception citing clinical contraindication to preferred alternatives or superior efficacy data from SURMOUNT trials
- Appeal if Denied: File internal appeal within 60 days, then external review through Washington State Office of the Insurance Commissioner if internal appeal denied
CHPW's Online Formulary tool at chpw.org/for-members/pharmacy allows real-time search for Zepbound status and current PA criteria, updated quarterly to reflect HCA policy changes.
Cost Considerations for CHPW Members
With CHPW Medicaid coverage, Zepbound typically carries a $0-$3 copay when prior authorization is approved, though patients should verify their specific plan tier (Apple Health standard vs. expansion) as costs vary.
Without Medicaid coverage, Zepbound's list price ranges from $550-$900/month depending on dosage (2.5mg to 15mg), making CHPW's restricted but existing coverage critical for Washington Medicaid members requiring tirzepatide therapy.
The Eli Lilly manufacturer savings card may supplement costs for commercially insured patients but generally does not apply to Medicaid beneficiaries due to federal anti-kickback statutes, limiting financial assistance options for CHPW members.
Expert Recommendations for Providers and Patients
Providers should document obstructive sleep apnea as the primary indication when possible, as this indication maintains stronger coverage probability under CHPW's 2026 policy compared to pure weight-loss claims.
- For patients under 21: Emphasize EPSDT benefit coverage for weight-loss indications with comprehensive growth chart documentation
- For adult patients: Focus OSA diagnosis with polysomnography results showing AHI ≥15 events/hour
- Document all prior weight-management interventions including 3-month supervised lifestyle program
- Request formulary exception if clinical contraindication exists to preferred GLP-1 alternatives
- Monitor CHPW formulary updates quarterly at chpw.org/bulletin-board/formulary-changes/
Patient advocacy groups recommend contacting CHPW Customer Service directly at 1-800-440-1561 when facing coverage denials, as phone-based appeals show 42% higher success rates than written-only submissions for GLP-1 medications.
Future Outlook: 2026-2027 Formulary Trends
Washington State's Health Care Authority signals potential expansion of GLP-1 coverage in late 2026 as federal Medicaid waiver discussions progress, but no confirmed timeline exists for lifting adult weight-loss restrictions before 2027.
The National Academy for State Health Policy reports that 23 states maintained weight-loss drug restrictions in 2026 Medicaid formularies, with only 7 states providing comprehensive GLP-1 coverage for obesity, positioning CHPW within the moderate-restriction category rather than the most restrictive tier.
As tirzepatide patents extend through 2032, biosimilar competition remains distant, suggesting CHPW's restricted access model will persist unless federal Medicaid policy shifts or state legislative action mandates expanded coverage for obesity treatment.
What are the most common questions about Chpw Formulary Update Where Does Zepbound Really Land?
Is Zepbound covered by CHPW in 2026?
Yes, Zepbound is covered on CHPW's 2026 formulary but requires prior authorization and is primarily covered for obstructive sleep apnea rather than weight loss; weight-loss coverage is restricted to members under 21 under EPSDT benefits.
What is the prior authorization requirement for Zepbound at CHPW?
CHPW requires prior authorization for Zepbound including documented BMI ≥35 kg/m² (or ≥30 with comorbidities), failure of 3-month lifestyle intervention, and for weight loss specifically, age under 21 under EPSDT; for OSA, documentation of apnea-hypopnea index ≥15 events/hour is required.
Does CHPW cover Zepbound for weight loss in 2026?
CHPW covers Zepbound for weight loss only for members younger than 21 years under the federal EPSDT benefit; adult weight-loss indications face severe restrictions or denial under 2026 policy updates effective April 1, 2026.
What indications does CHPW prefer for Zepbound coverage?
CHPW preferentially covers Zepbound for obstructive sleep apnea (OSA) with BMI ≥35 kg/m², as this indication maintains stronger medical necessity justification compared to pure weight-loss claims under 2026 Washington state Medicaid policy.
When does the CHPW 2026 formulary update take effect?
The CHPW 2026 formulary update with HCA policy changes takes effect April 1, 2026, affecting all CHPW Apple Health (Medicaid) members, with prior authorization criteria updated for metabolic and cytokine inhibitor medications.
How do I contact CHPW about Zepbound coverage?
Contact CHPW Customer Service at 1-800-440-1561 Monday through Friday from 8am to 5pm, or visit chpw.org/for-members/pharmacy for online formulary search and prior authorization forms.
Will CHPW cover Zepbound if Wegovy fails?
Yes, if Wegovy fails or is contraindicated, providers can request a formulary exception for Zepbound by documenting clinical failure (insufficient weight loss